Toggle navigation
Menu
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
73°
Search
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Local Weather
News
Sports
Entertainment
Calendar
Games
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Town & Gown
Subscribe
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Eiger Biopharma
(NQ:
EIGR
)
10.73
USD
+0.18 (+1.71%)
Official Closing Price
Updated: 5:26 PM EST, Jan 22, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All news about Eiger Biopharma
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Mid-Morning Market Update: Markets Gain; Citigroup Earnings Top Estimates
July 14, 2017
Following the market opening Friday, the Dow traded up 0.18 percent to 21,571.42 while the NASDAQ climbed 0.20 percent to 6,287.06. The ...
Tags
GCBC
EIGR
DGICA
From
Benzinga
Benzinga's Top Upgrades, Downgrades For July 14, 2017
July 14, 2017
Top Upgrades Analysts at JP Morgan upgraded Boeing Co (NYSE: BA) from Neutral to Overweight. Boeing shares rose 0.83 percent ...
Tags
BA
MGLN
Downgrades
From
Benzinga
Sum Up The Pieces: VTWG Could Be Worth $136
July 11, 2017
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...
Tags
ETFs
From
ETF Channel
Premarket Biotech Digest – PFE receives EU approval, ALKS announces positive results, SRNE receives FDA approval
June 30, 2017
Pfizer Inc. announced receiving the European Commission’s approval for Besponsa treatment for adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
Tags
Stocks / Equities
Pharma/Biotech
Healthcare
From
Blogs - TalkMarkets
BRIEF-Eiger BioPharma announces sale of non-strategic assets to Theragene Pharma
June 29, 2017
* Eiger BioPharmaceuticals announces sale of non-strategic assets to Theragene Pharmaceuticals
Tags
companyNews
From
Reuters: Company News
Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals
June 29, 2017
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), announced today an agreement to sell to Theragene Pharmaceuticals, Inc., a private biotechnology company, a non-strategic asset, Mydicar® (rAAV1-SERCA2a)....
From
PR Newswire
BRIEF-Eiger names David Apelian to board of directors
June 14, 2017
* Eiger announces appointment of biopharmaceutical industry veteran David Apelian, MD, PHD, MBA to its board of directors Source text for Eikon: Further company coverage:
Tags
companyNews
From
Reuters: Company News
Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors
June 14, 2017
- Company Prepares to Advance Orphan Disease Pipeline
From
PR Newswire
BRIEF-Eiger reports additional positive phase 2 results from multiple-ascending dose study of exendin 9-39
June 12, 2017
* Eiger reports additional positive phase 2 results from multiple-ascending dose study of exendin 9-39 in post-bariatric hypoglycemia patients at american diabetes association meeting in san diego
Tags
companyNews
From
Reuters: Company News
Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego
June 12, 2017
- Novel Liquid Formulation of Subcutaneous Exendin 9-39 Highlighted
From
PR Newswire
BRIEF-Eiger completes enrollments for phase 2 in hypoglycemia study
June 06, 2017
* Eiger completes enrollment in phase 2 multiple-ascending dose study of exendin 9-39 in post-bariatric hypoglycemia patients Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1...
Tags
companyNews
From
Reuters: Company News
Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients
June 06, 2017
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced completion of enrollment of the Phase 2 multiple-ascending...
From
PR Newswire
Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7th
May 30, 2017
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger,...
From
PR Newswire
BRIEF-Eiger announces results of ubenimex and leukotriene b4 (LTB4) modulation in experimental lymphedema
May 17, 2017
* Eiger announces results demonstrating benefit of ubenimex and leukotriene B4 (LTB4) modulation in experimental lymphedema Source text for Eikon: Further company coverage:
Tags
companyNews
From
Reuters: Company News
Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema
May 17, 2017
- Data Supports Ongoing Phase 2 ULTRA Study of Ubenimex in Lymphedema
From
PR Newswire
BRIEF-Eiger Biopharmaceuticals says completes enrollment of phase 2 liberty study of ubenimex
May 15, 2017
* Eiger Biopharmaceuticals Inc says completes enrollment of phase 2 liberty study of ubenimex in pulmonary arterial hypertension Source text for Eikon: Further company coverage:
Tags
companyNews
From
Reuters: Company News
Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension
May 15, 2017
- Phase 2 LIBERTY Data Expected First Quarter 2018
From
PR Newswire
BRIEF-Eiger BioPharma Q1 loss per share $1.34
May 12, 2017
* Eiger biopharmaceuticals reports first quarter 2017 financial results
Tags
companyNews
From
Reuters: Company News
Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results
May 12, 2017
- Five Phase 2 Programs in Four Orphan Indications Progressing
From
PR Newswire
Eiger Announces Presentation of Prevalence Data of Hepatitis Delta Virus (HDV) Infection in the U.S. at Digestive Disease Week (DDW) in Chicago
May 08, 2017
Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced HDV/HBV co-infection prevalence data from an International Classification of Diseases (ICD) analysis presented at Digestive Disease Week...
From
PR Newswire
Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City
May 04, 2017
- Phase 2 LIBERTY Study Update for Ubenimex in PAH
From
PR Newswire
BRIEF-Eiger says filed U.S. IND for its treatment for HDV infection
May 03, 2017
* Eiger announces U.S. IND filing of pegylated interferon lambda for hepatitis delta virus infection Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)
Tags
companyNews
From
Reuters: Company News
Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection
May 03, 2017
- LIMT HDV: Lambda Interferon MonoTherapy in HDV Study Enrolling
From
PR Newswire
Eiger Announces Abstract and Presentation at 2017 Digestive Disease Week in Chicago
April 24, 2017
Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that an abstract describing prevalence of hepatitis delta virus (HDV) in the U.S. will be presented at Digestive Disease Week (DDW) in...
From
PR Newswire
BRIEF-Eiger announces additional phase 2 clinical trial results
April 21, 2017
* Eiger announces additional phase 2 clinical trial results for lonafarnib at the international liver congress 2017
Tags
companyNews
From
Reuters: Company News
Eiger Announces Additional Phase 2 Clinical Trial Results for Lonafarnib at The International Liver Congress™ 2017
April 21, 2017
Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced additional supportive and encouraging lonafarnib (LNF) data from the LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program...
From
PR Newswire
Eiger Announces Industry Veteran Lisa Porter, M.D. to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia
April 18, 2017
- Novel Liquid Formulation of Exendin 9-39 Advancing
From
PR Newswire
Analysts Forecast 13% Upside For IWO
April 07, 2017
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...
Tags
ETFs
From
ETF Channel
Eiger Announces Abstracts and Presentations of LOWR HDV Program at the European Association for the Study of the Liver (EASL) Meeting
April 06, 2017
Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that abstracts from its LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program will be presented at the European...
From
PR Newswire
BRIEF-Eiger Biopharmaceuticals Q4 loss per share $1.53
March 23, 2017
* Eiger biopharmaceuticals reports fourth quarter and full year 2016 financial results
Tags
companyNews
From
Reuters: Company News
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.